Loading clinical trials...

Initial Resuscitation With Albumin in Hemorrhagic Shock to Reduce Positive Fluid Balance | Clinical Trials | Clareo Health

UNKNOWNNA

Initial Resuscitation With Albumin in Hemorrhagic Shock to Reduce Positive Fluid Balance

Initial Resuscitation With Albumin in Hemorrhagic Shock to Reduce Positive Fluid Balance: A Randomized Controlled Trial (ABSOLUTE Trial)

NCT06111261•Seoul National University Hospital

View on ClinicalTrials.gov

Summary

This study is designed to evaluate the effect of early albumin transfusion within massive transfusion protocol on fluid balance and reduced requirement of transfusion.

Detailed Description

Eligible patients who require massive transfusion will be randomized in a single-blind manner (participant) in a 1:1 ratio to Conventional Massive Transfusion Pro. tocol group (C-MTP) or Albumin Massive Transfusion Protocol group (A-MTP). When MTP is initiated according to the result of randomization, all patients(or a legal guardian) are informed about the study and potential risks and benefits. Study will be continued only in patients who give informed consent.

Eligibility

Age

19 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Adult patients (19 or older)
•Admitted or planned to admit surgical intensive care unit
•Patients with decreased hemoglobin level more than 20% from baseline within 12 hours, Or
•Patients who are suspected bleeding and hemodynamically unstable requiring more than 0.05mcg/kg/min of norepinephrine infusion to maintain mean blood pressure higher than 65mmHg

Exclusion Criteria

•Contraindicated to albumin product
•patients with risk factors of increased circulatory volume (heart failure, pulmonary edema, end-stage renal disease with oliguria)
•patients with hemolytic anemia
•History of anaphylactic reaction to blood product

Key Dates

Start Date

November 15, 2023

Primary Completion Date

July 15, 2025

Completion Date

August 15, 2025

Last Updated

November 1, 2023

Enrollment

ESTIMATED participants

Conditions

BleedingMassive HemorrhageMassive Transfusion Protocol

Interventions

Albumin solution

DRUG

Balanced crystalloid solution

DRUG

Contacts

Leerang Lim, M.D.

CONTACT

+82-2-2072-2467 erange@snu.ac.kr

Seung-young Oh, M.D.

CONTACT

+82-2-2072-2966 faun1224@gmail.com

Factor VIII Inhibitor Bypass Activity (FEIBA) Versus Fresh Frozen Plasma As First Line Therapy For Bleeding After Cardiac Surgery

NCT07032792

Cardiac DiseaseSurgery+1 more

View study

RECRUITING

National Longitudinal Cohort of Hematological Diseases

NCT04645199

Multiple MyelomaAcute Myeloid Leukemia+15 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 1, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Initial Resuscitation With Albumin in Hemorrhagic Shock to Reduce Positive Fluid Balance

Inclusion Criteria

Exclusion Criteria

Factor VIII Inhibitor Bypass Activity (FEIBA) Versus Fresh Frozen Plasma As First Line Therapy For Bleeding After Cardiac Surgery

National Longitudinal Cohort of Hematological Diseases

Point of Care Fibrinogen Measurement in Trauma Patients in the Emergency Department

Isolated Rectal Bleeding in Newborns : Allergic Proctocolitis or Neonatal Colitis Transient - COLON Study

Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO IV-EPIC 38)

Management of Gastrointestinal Bleeding Under Direct Oral Anticoagulants